Foamix Pharmaceuticals Ltd. (FOMX) : Traders are getting increasingly bearish on Foamix Pharmaceuticals Ltd. (FOMX), as can be seen in the addition of short positions from 1,759,411 on Jul 29, 2016, to 1,853,410 on August 15, 2016. The net change in shorts is 93,999 shares, an increase of 5.3%. 13 days remain before the expiry. The 7.8% of outstanding short positions on the stock compared to its float, shows that traders expect the stock to fall from the current levels. The daily volume of the stock is 144,164. The short interest information was released on Wednesday Aug 24th after the market close.
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The stock opened at $8.81 on Wednesday but the bulls could not build on the opening and the stock topped out at $8.96 for the day. The stock traded down to $8.27 during the day, due to lack of any buying support eventually closed down at $8.40 with a loss of -4.55% for the day. The stock had closed at $8.80 on the previous day. The total traded volume was 92,810 shares.
Foamix Pharmaceuticals Ltd. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its minocycline foam for the treatment of acne, impetigo and other skin conditions. The Companys product candidates include, FMX101 for moderate-to-severe acne, is a topical foam formulation of the antibiotic minocycline; FMX102 for impetigo, FMX103 for rosacea and FDX104 for chemotherapy-induced rash. The Company has conducted only one Phase II clinical trial of each of FMX101 and FMX102 which met the respective primary efficacy and secondary endpoints. The Company developed FMX101, FMX102, FMX103 and FDX104 using its technology, which includes its foam-based platforms. This technology enables it to formulate and stabilize a variety of drugs and deliver them directly to target site. The Company has entered into development and license agreements relating to its technology with Bayer HealthCare AG (Intendis), Merz Pharmaceuticals, LLC and Actavis plc.